Log In
Print this Print this

Nplate, Romiplate, romiplostim

Also known as: formerly AMG 531

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionRecombinant fusion protein containing a pair of thrombopoietin (TPO) receptor-binding domains
Molecular Target Thrombopoietin (TPO) receptor (CD110) (Mpl)
Mechanism of ActionThrombopoietin (TPO) receptor (CD110) (Mpl) agonist
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationIdiopathic thrombocytopenic purpura (ITP)
Indication DetailsTreat chemotherapy-induced idiopathic thrombocytopenic purpura (ITP); Treat chronic idiopathic thrombocytopenic purpura (ITP); Treat idiopathic thrombocytopenic purpura (ITP)
Regulatory Designation Switzerland - Orphan Drug (Treat chronic idiopathic thrombocytopenic purpura (ITP))
Partner Kyowa Hakko Kirin Co. Ltd.; Kyowa Hakko Kirin Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today